News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Articles|December 1, 2004

Clinician to Clinician: Have you ruled out a placental site nodule?

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

Amber Watters, MD, on emergency preparedness and building a version program

Amber Watters, MD, on emergency preparedness and building a version program

ByAmber Watters, MD, MS

September 11th 2026

New tool translates pregnancy test research into individualized patient counseling resource

ByAlexandra C. Sundermann, MD, PhD

September 11th 2026

Kevin Ault, MD, on maternal immunization as a bridge to pediatric vaccination

ByKevin Ault, MD

September 11th 2026

Image credit: Society of Family Planning

Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal

ByJoshua Fitch, Senior Editor

September 10th 2026

Phase 3 LUNA study: atogepant reduces menstrual migraine days vs. placebo

Phase 3 LUNA study: atogepant reduces menstrual migraine days vs. placebo

ByJoshua Fitch, Senior Editor

September 10th 2026

Latest CME

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal

Amber Watters, MD, on emergency preparedness and building a version program

Phase 3 LUNA study: atogepant reduces menstrual migraine days vs. placebo

PMOS Awareness Month: Watch our expert panel discussion on PMOS

Certolizumab pegol receives FDA BTD for adverse pregnancy outcomes in APS